Oligonucleotide Therapeutics Market Outlook

Global Oligonucleotide Therapeutics Market Size - By Oligonucleotides Class, By Therapeutic Area, By Route of Administration - Regional Outlook, Competitive Strategies and Segment Forecast to 2035

Published: Jan-2026	Report ID: HLCA2605	Pages: 1 - 250	Formats^*:
Category : Healthcare

According to SPER Market Research, the Global Oligonucleotide Therapeutics Market is estimated to reach USD 43.3 billion by 2035 with a CAGR 19.65%.

Introduction and Overview

The report includes an in-depth analysis of the Global Oligonucleotide Therapeutics Market, including market size and trends, product mix, Applications, and supplier analysis.

The global Oligonucleotide Therapeutics Market was valued at USD 7.2 billion in 2025 and is expected to reach USD 43.3 billion by 2035, registering a CAGR of 19.65% during the forecast period. Advancements in antisense oligonucleotides, siRNA therapies, and other RNA-targeting technologies are broadening the use of gene-modulating treatments across multiple disease areas. Ongoing improvements in delivery platforms, including lipid nanoparticles and GalNAc conjugates, are enhancing drug stability, targeted delivery, cellular uptake, and therapeutic effectiveness. The market is further supported by a growing number of regulatory approvals, expanding clinical development programs, and increasing commercialization of RNA-based medicines. These factors are boosting industry confidence, attracting investment, and accelerating the development of innovative nucleic acid therapeutics and precision medicine solutions worldwide.

By Oligonucleotides Class:

The antisense oligonucleotide segment holds a leading position in the market, supported by rising use of RNA-targeting therapies for rare genetic, neurological, and immune-related disorders. Advances in oligonucleotide chemistry and delivery technologies are improving stability, targeting accuracy, and therapeutic outcomes. Growing regulatory support, commercialization efforts, and investments in ligand-conjugated platforms are further driving innovation. Meanwhile, the microRNA segment is expected to witness strong growth due to expanding applications in oncology and genetic disorders. Improvements in gene-silencing technologies, sequence design, and delivery systems are enhancing target specificity, stability, and cellular uptake, supporting broader adoption in precision medicine.

By Therapeutic Area:

The neurology segment leads the market due to increasing use of RNA-targeting therapies for neurological and neurodegenerative disorders with limited treatment options. Rising cases of inherited conditions, genetic epilepsy syndromes, and neurodevelopmental disorders are supporting demand for innovative treatments. Antisense oligonucleotides and siRNA therapies are gaining attention for their ability to regulate disease-related genes and protein expression. Advances in central nervous system delivery technologies and growing pharmaceutical investment are further driving innovation. Meanwhile, the cardiometabolic disorders segment is expected to grow rapidly, supported by increasing cardiovascular disease prevalence and the adoption of RNA-based therapies for targeted metabolic regulation.

By Route of Administration:

The subcutaneous segment holds a leading market position due to its compatibility with antisense oligonucleotide and siRNA therapies. Advances in delivery technologies, including targeted conjugation approaches, have improved therapeutic effectiveness, particularly for liver-related genetic and cardiometabolic conditions. Its minimally invasive nature, suitability for self-administration, and support for long-acting treatments enhance patient convenience and adherence. Growing regulatory approvals and expanding clinical pipelines further strengthen its adoption. Meanwhile, the intramuscular segment is expected to experience notable growth, supported by its ability to provide sustained drug absorption, gradual release, and prolonged therapeutic activity in selected nucleic acid-based treatments.

Regional Insights:

North America leads the oligonucleotide therapeutics market, supported by a strong biotechnology ecosystem, advanced research capabilities, high healthcare expenditure, and widespread adoption of precision medicine. The region benefits from the presence of major RNA-focused companies, supportive regulatory frameworks, extensive clinical research, and continued investment in manufacturing and delivery technologies. The United States remains the primary contributor due to its leadership in RNA-based drug development and commercialization. Asia Pacific is expected to witness the fastest growth, driven by expanding biotechnology investments, increasing genomic research, supportive government initiatives, and rising demand for targeted therapies. Europe continues to grow steadily, supported by strong research infrastructure, precision medicine adoption, and favorable regulatory support for rare disease treatments.

Market Competitive Landscape:

The Global Oligonucleotide Therapeutics Market is highly consolidated. Some of the market key players are Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Biogen, Ionis Pharmaceuticals, Nitto Denko Avecia, Novartis, Roche, Sarepta Therapeutics, Silence Therapeutics, and Wave Life Sciences.

Recent Developments:

In March 2025, Ionis Pharmaceuticals expanded its partnership with Sobi to commercialize olezarsen (TRYNGOLZA) outside the U.S., enhancing global access and strengthening its cardiometabolic antisense therapy portfolio.
In February 2025, Sarepta Therapeutics entered a licensing and collaboration agreement with Arrowhead Pharmaceuticals to develop RNAi therapies for rare genetic, neuromuscular, and CNS disorders, strengthening its genetic medicine pipeline.

Scope of the report:

Report Metric	Details
Market size available for years	2022-2035
Base year considered	2025
Forecast period	2026-2035
Segments covered	by Oligonucleotide Class, By Therapeutic Area, By Route of Administration
Regions covered	North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered	Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Biogen, Ionis Pharmaceuticals, Nitto Denko Avecia, Novartis, Roche, Sarepta Therapeutics, Silence Therapeutics, and Wave Life Sciences.

Key Topics Covered in the Report

Global Oligonucleotide Therapeutics Market Size (FY’2022-FY’2035)
Overview of Global Oligonucleotide Therapeutics Market
Segmentation of Global Oligonucleotide Therapeutics Market by Oligonucleotide Class {Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Aptamers, microRNA (miRNA), CpG Oligonucleotides, Other}
Segmentation of Global Oligonucleotide Therapeutics Market by Therapeutic Area (Neurology, Oncology, Cardiometabolic Disorders, Infectious Diseases, Ophthalmology, Other)
Segmentation of Global Oligonucleotide Therapeutics Market by Route of Administration (Subcutaneous, Intravenous, Intrathecal, Intramuscular, Other)
Statistical Snap of Global Oligonucleotide Therapeutics Market
Expansion Analysis of the Global Oligonucleotide Therapeutics Market
Problems and Obstacles in the Global Oligonucleotide Therapeutics Market
Competitive Landscape in the Global Oligonucleotide Therapeutics Market
Details on Current Investment in the Global Oligonucleotide Therapeutics Market
Competitive Analysis of the Global Oligonucleotide Therapeutics Market
Prominent Players in the Global Oligonucleotide Therapeutics Market
SWOT Analysis of Global Oligonucleotide Therapeutics Market
Global Oligonucleotide Therapeutics Market Future Outlook and Projections (FY’2026-FY’2035)
Recommendations from Analyst

1. Introduction

1.1 Scope of the report
1.2 Market segment analysis

2. Research Methodology

2.1 Research data source

2.1.1 Secondary Data
2.1.2 Primary Data
2.1.3 SPER’s internal Database
2.1.4 Primary insight from KOL’s

2.2 Market size estimation

2.2.1 Top-down and Bottom-up approach

2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1 Driver, Restraint, Opportunity and Challenges analysis

4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges

5. Market variable and outlook

5.1 SWOT Analysis

5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats

5.2 PESTEL Analysis

5.2.1 Political Landscape
5.2.2 Economic Landscape
5.2.3 Social Landscape
5.2.4 Technological Landscape
5.2.5 Environmental Landscape
5.2.6 Legal Landscape

5.3 PORTER’s Five Forces
5.4 Heat Map Analysis

6. Competitive Landscape

6.1. Global Oligonucleotide Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Oligonucleotide Therapeutics Market

7. Global Oligonucleotide Therapeutics Market, By Oligonucleotide Class, (USD Million) 2022-2035

7.1 Antisense Oligonucleotides (ASOs)
7.2 Small Interfering RNA (siRNA)
7.3 Aptamers
7.4 microRNA (miRNA)
7.5 CpG Oligonucleotides
7.6 Other

8. Global Oligonucleotide Therapeutics Market, By Therapeutic Area, (USD Million) 2022-2035

8.1 Neurology
8.2 Oncology
8.3 Cardiometabolic Disorders
8.4 Infectious Diseases
8.5 Ophthalmology
8.6 Other

9. Global Oligonucleotide Therapeutics Market, By Route of Administration, (USD Million) 2022-2035

9.1 Subcutaneous
9.2 Intravenous
9.3 Intrathecal
9.4 Intramuscular
9.5 Other

10. Global Oligonucleotide Therapeutics Market, (USD Million) 2022-2035

10.1 Global Oligonucleotide Therapeutics Market Size and Market Share

11. Global Oligonucleotide Therapeutics Market, By Region, (USD Million) 2022-2035

11.1 Asia-Pacific

11.1.1 Australia
11.1.2 China
11.1.3 India
11.1.4 Japan
11.1.5 South Korea
11.1.6 Rest of Asia-Pacific

11.2 Europe

11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Rest of Europe

11.3 Middle East and Africa

11.3.1 Kingdom of Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Qatar
11.3.4 South Africa
11.3.5 Egypt
11.3.6 Morocco
11.3.7 Nigeria
11.3.8 Rest of Middle-East and Africa

11.4 North America

11.4.1 Canada
11.4.2 Mexico
11.4.3 United States

11.5 Latin America

11.5.1 Argentina
11.5.2 Brazil
11.5.3 Rest of America

12. Company Profile

12.1 Alnylam Pharmaceuticals

12.1.1 Company details
12.1.2 Financial outlook
12.1.3 Product summary
12.1.4 Recent developments

12.2 Arrowhead Pharmaceuticals

12.2.1 Company details
12.2.2 Financial outlook
12.2.3 Product summary
12.2.4 Recent developments

12.3 Biogen

12.3.1 Company details
12.3.2 Financial outlook
12.3.3 Product summary
12.3.4 Recent developments

12.4 Ionis Pharmaceuticals

12.4.1 Company details
12.4.2 Financial outlook
12.4.3 Product summary
12.4.4 Recent developments

12.5 Nitto Denko Avecia

12.5.1 Company details
12.5.2 Financial outlook
12.5.3 Product summary
12.5.4 Recent developments

12.6 Novartis

12.6.1 Company details
12.6.2 Financial outlook
12.6.3 Product summary
12.6.4 Recent developments

12.7 Roche

12.7.1 Company details
12.7.2 Financial outlook
12.7.3 Product summary
12.7.4 Recent developments

12.8 Sarepta Therapeutics

12.8.1 Company details
12.8.2 Financial outlook
12.8.3 Product summary
12.8.4 Recent developments

12.9 Silence Therapeutics

12.9.1 Company details
12.9.2 Financial outlook
12.9.3 Product summary
12.9.4 Recent developments

12.10 Wave Life Sciences

12.10.1 Company details
12.10.2 Financial outlook
12.10.3 Product summary
12.10.4 Recent developments

12.11 Others

13. Conclusion

14. List Of Abbreviations

15. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1